Daniel Sherbenou
Associate Professor · University of Colorado School of Medicine
Credentials: · · · ·
History
Research
The Lancet Haematology · 2019 · 216 citations
Characterization of murine JAK2V617F-positive myeloproliferative disease
Cancer Research · 2006 · 159 citations
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2023 · 137 citations
- PF
16 papers
- TM
13 papers
8 papers
6 papers
6 papers · 5 as a resident
5 papers
5 papers
5 papers
Grants
- 2018–2023
Targeting Cancer Initiating Cells in Multiple Myeloma
National Cancer Institute · K08
Contact PI · $1.1M · University of Colorado Denver
Clinical trials
- 2021–2026
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Principal investigator · Active not recruiting · Phase 2
University of Colorado, Denver
- 2023–2027
Site PI · Recruiting · Phase 1
Caribou Biosciences, Inc.
- 2026–2030
Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
Sub-investigator · Recruiting · Phase 2
University of Colorado, Denver
- 2024–2027
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Sub-investigator · Recruiting · Phase 1
University of Colorado, Denver